Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab (VAY RE-HIT)
Exploratory Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab (VAY RE-HIT)
Sponsor: Novartis Pharmaceuticals
This PHASE2 trial investigates Primary Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia and is currently actively recruiting participants. Novartis Pharmaceuticals leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .